Valve Tissue Characterization by Magnetic Resonance Imaging in Calcific Aortic Valve Disease

Canadian Journal of Cardiology

Volumn 30, Issue 12, 2014, Pages 1676-1683

  Le Ven, Florent ^a   Tizón Marcos, Helena ^a   Fuchs, Christina ^a   Mathieu, Patrick ^a   Pibarot, Philippe ^a   Larose, Eric ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID;

AGED; AORTA STENOSIS; AORTA VALVE; AORTA VALVE DISEASE; AREA UNDER THE CURVE; ARTERY CALCIFICATION; ARTICLE; CALCIFIC AORTIC VALVE DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION WEIGHTED IMAGING; EX VIVO STUDY; FEMALE; FIBROSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MALE; MINERALIZATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; AORTIC VALVE STENOSIS; CALCINOSIS; COMPLICATION; FOLLOW UP; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX;

AGED; AORTIC VALVE; AORTIC VALVE STENOSIS; CALCINOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING, CINE; MALE; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX;

EID: 84919706044     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.09.036     Document Type: Article

References (45)

1. Supino P.G., Borer J.S., Preibisz J., Bornstein A. The epidemiology of valvular heart disease: a growing public health problem. Heart Fail Clin 2006, 2:379-393.
2. Helske S., Otto C.M. Lipid lowering in aortic stenosis: still some light at the end of the tunnel?. Circulation 2009, 119:2653-2655.
3. Akat K., Borggrefe M., Kaden J.J. Aortic valve calcification: basic science to clinical practice. Heart 2009, 95:616-623.
4. CÔté C., Pibarot P., Després J.-P., et al. Association between circulating oxidised low-density lipoprotein and fibrocalcific remodelling of the aortic valve in aortic stenosis. Heart 2008, 94:1175-1180.
5. Stewart B.F., Siscovick D., Lind B.K., et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. JAm Coll Cardiol 1997, 29:630-634.
6. Cowell S.J., Newby D.E., Prescott R.J., et al. Arandomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. NEngl J Med 2005, 352:2389-2397.
7. Rossebø A.B., Pedersen T.R., Boman K., et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. NEngl J Med 2008, 359:1343-1356.
8. Capoulade R., Clavel M.-A., Dumesnil J.G., et al. Impact of metabolic syndrome on progression of aortic stenosis: influence of age and statin therapy. JAm Coll Cardiol 2012, 60:216-223.
9. Bossé Y., Miqdad A., Fournier D., et al. Refining molecular pathways leading to calcific aortic valve stenosis by studying gene expression profile of normal and calcified stenotic human aortic valves. Circ Cardiovasc Genet 2009, 2:489-498.
10. Derbali H., Bossé Y., CÔté N., et al. Increased biglycan in aortic valve stenosis leads to the overexpression of phospholipid transfer protein via Toll-like receptor 2. Am J Pathol 2010, 176:2638-2645.
11. Leber A.W., Becker A., Knez A., et al. Accuracy of 64-slice computed tomography to classify and quantify plaque volumes in the proximal coronary system: a comparative study using intravascular ultrasound. JAm Coll Cardiol 2006, 47:672-677.
12. Larose E., Yeghiazarians Y., Libby P., et al. Characterization of human atherosclerotic plaques by intravascular magnetic resonance imaging. Circulation 2005, 112:2324-2331.
13. Larose E., Kinlay S., Selwyn A.P., et al. Improved characterization of atherosclerotic plaques by gadolinium contrast during intravascular magnetic resonance imaging of human arteries. Atherosclerosis 2008, 196:919-925.
14. Whittaker P., Kloner R.A., Boughner D.R., Pickering J.G. Quantitative assessment of myocardial collagen with picrosirius red staining and circularly polarized light. Basic Res Cardiol 1994, 89:397-410.
15. Dunmore-Buyze J., Boughner D.R., Macris N., Vesely I. Acomparison of macroscopic lipid content within porcine pulmonary and aortic valves. Implications for bioprosthetic valves. JThorac Cardiovasc Surg 1995, 110:1756-1761.
16. Wysokiński A., Zapolski T. Relationship between aortic valve calcification and aortic atherosclerosis: a transoesophageal echocardiography study. Kardiol Pol 2006, 64:694-701. discussion 702-3.
17. Nemcsik J., Farkas K., Kolossváry E., et al. Intracardiac calcification is a marker of generalized atherosclerosis. Angiology 2007, 58:413-419.
18. Rosenhek R., Binder T., Porenta G., et al. Predictors of outcome in severe, asymptomatic aortic stenosis. NEngl J Med 2000, 343:611-617.
19. Owens D.S., Budoff M.J., Katz R., et al. Aortic valve calcium independently predicts coronary and cardiovascular events in a primary prevention population. JACC Cardiovasc Imaging 2012, 5:619-625.
20. CÔté N., Couture C., Pibarot P., Després J.-P., Mathieu P. Angiotensin receptor blockers are associated with a lower remodelling score of stenotic aortic valves. Eur J Clin Invest 2011, 41:1172-1179.
21. Novaro G.M., Tiong I.Y., Pearce G.L., et al. Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation 2001, 104:2205-2209.
22. Shavelle D.M., Takasu J., Budoff M.J., et al. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 2002, 359:1125-1126.
23. Rosenhek R., Rader F., Loho N., et al. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 2004, 110:1291-1295.
24. O'Brien K.D., Zhao X.-Q., Shavelle D.M., et al. Hemodynamic effects of the angiotensin-converting enzyme inhibitor, ramipril, in patients with mild to moderate aortic stenosis and preserved left ventricular function. JInvestig Med 2004, 52:185-191.
25. Chockalingam A., Venkatesan S., Subramaniam T., et al. Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis (SCOPE-AS). Am Heart J 2004, 147:E19.
26. Ahmed A., Kiefe C.I., Allman R.M., Sims R.V., DeLong J.F. Survival benefits of angiotensin-converting enzyme inhibitors in older heart failure patients with perceived contraindications. JAm Geriatr Soc 2002, 50:1659-1666.
27. Ahmed A., Centor R.M., Weaver M.T., Perry G.J. Apropensity score analysis of the impact of angiotensin-converting enzyme inhibitors on long-term survival of older adults with heart failure and perceived contraindications. Am Heart J 2005, 149:737-743.
28. Willmann J.K., Weishaupt D., Lachat M., et al. Electrocardiographically gated multi-detector row CT for assessment of valvular morphology and calcification in aortic stenosis. Radiology 2002, 225:120-128.
29. Pouleur A.-C., le Polain de Waroux J.-B., Pasquet A., Vanoverschelde J.-L.J., Gerber B.L. Aortic valve area assessment: multidetector CT compared with cine MR imaging and transthoracic and transesophageal echocardiography. Radiology 2007, 244:745-754.
30. Cueff C., Serfaty J.-M., Cimadevilla C., et al. Measurement of aortic valve calcification using multislice computed tomography: correlation with haemodynamic severity of aortic stenosis and clinical implication for patients with low ejection fraction. Heart 2011, 97:721-726.
31. Koos R., Mahnken A.H., Sinha A.M., Wildberger J.E., Hoffmann R., Kühl H.P. Aortic valve calcification as a marker for aortic stenosis severity: assessment on 16-MDCT. AJR Am J Roentgenol 2004, 183:1813-1818.
32. Jahnke C., Hamdan A., Fleck E., Paetsch I. Tissue characterization of a suspected aortic valve fibroelastoma with cardiac magnetic resonance imaging. Circ Cardiovasc Imaging 2008, 1:87-88.
33. Thanassoulis G., Massaro J.M., Cury R., et al. Associations of long-term and early adult atherosclerosis risk factors with aortic and mitral valve calcium. JAm Coll Cardiol 2010, 55:2491-2498.
34. Mahmut A., Boulanger M.-C., Fournier D., et al. Lipoprotein lipase in aortic valve stenosis is associated with lipid retention and remodelling. Eur J Clin Invest 2013, 43:570-578.
35. Kamstrup P.R., Tybjærg-Hansen A., Nordestgaard B.G. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. JAm Coll Cardiol 2014, 63:470-477.
36. Arsenault B.J., Boekholdt S.M., Dubé M.-P., et al. Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective mendelian randomization study and replication in a case-control cohort. Circ Cardiovasc Genet 2014, 7:304-310.
37. Saam T., Ferguson M.S., Yarnykh V.L., et al. Quantitative evaluation of carotid plaque composition by invivo MRI. Arterioscler Thromb Vasc Biol 2005, 25:234-239.
38. Fabiano S., Mancino S., Stefanini M., et al. High-resolution multicontrast-weighted MR imaging from human carotid endarterectomy specimens to assess carotid plaque components. Eur Radiol 2008, 18:2912-2921.
39. Yuan C., Kerwin W.S., Ferguson M.S., et al. Contrast-enhanced high resolution MRI for atherosclerotic carotid artery tissue characterization. JMagn Reson Imaging 2002, 15:62-67.
40. Korosoglou G., Weiss R.G., Kedziorek D.A., et al. Noninvasive detection of macrophage-rich atherosclerotic plaque in hyperlipidemic rabbits using "positive contrast" magnetic resonance imaging. JAm Coll Cardiol 2008, 52:483-491.
41. Hamilton A.M., Rogers K.A., Belisle A.J.L., et al. Early identification of aortic valve sclerosis using iron oxide enhanced MRI. JMagn Reson Imaging 2010, 31:110-116.
42. Flett A.S., Hayward M.P., Ashworth M.T., et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation 2010, 122:138-144.
43. Anderson L.J., Holden S., Davis B., et al. Cardiovascular T2-star (T2) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001, 22:2171-2179.
44. Yuan C., Mitsumori L.M., Beach K.W., Maravilla K.R. Carotid atherosclerotic plaque: noninvasive MR characterization and identification of vulnerable lesions. Radiology 2001, 221:285-299.
45. Ferreira P.F., Gatehouse P.D., Mohiaddin R.H., Firmin D.N. Cardiovascular magnetic resonance artefacts. JCardiovasc Magn Reson 2013, 15:41.